Slingshot members are tracking this event:

Halozyme Therapeutics (HALO) to begin Phase 1b open label study—under MORPHEUS platform—on combination Tecentriq and PEG PH20 treating metastatic biliary of gallbladder cancer in second half of 2017

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks
HALO Community voting in process
Slingshot Insights Explained
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Morpheus, Phase 1b, Tecentriq, Pegph20, Metastatic Biliary, Gallbladder Tumors